BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wu L, Sun B, Lin X, Liu C, Qian H, Chen L, Yang Y, Shen F, Su C. I131 reinforces antitumor activity of metuximab by reversing epithelial-mesenchymal transition via VEGFR-2 signaling in hepatocellular carcinoma. Genes Cells 2018;23:35-45. [PMID: 29210217 DOI: 10.1111/gtc.12545] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
Number Citing Articles
1 Chen H, Teng M, Zhang H, Liang X, Cheng H, Liu G. Advanced radionuclides in diagnosis and therapy for hepatocellular carcinoma. Chinese Chemical Letters 2022. [DOI: 10.1016/j.cclet.2022.03.079] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Rahat MA. Mini-Review: Can the Metastatic Cascade Be Inhibited by Targeting CD147/EMMPRIN to Prevent Tumor Recurrence? Front Immunol 2022;13:855978. [PMID: 35418981 DOI: 10.3389/fimmu.2022.855978] [Reference Citation Analysis]
3 Gurzu S, Kobori L, Fodor D, Jung I. Epithelial Mesenchymal and Endothelial Mesenchymal Transitions in Hepatocellular Carcinoma: A Review. Biomed Res Int 2019;2019:2962580. [PMID: 31781608 DOI: 10.1155/2019/2962580] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 8.3] [Reference Citation Analysis]